Implementing pathways to encourage competition and placing government regulation on generic drugs that lack competition were two suggestions offered during this week's Senate Special Committee on Aging to tackle a recent spate of off-patent drug hikes epitomized by Turing Pharmaceuticals Inc., which raised the price on a 62-year-old drug by nearly 5,500 percent and limited its access to specialty pharmacies.